Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GroPep Limited
Phase I clinical trial of infertility drug underway
February 5th, 2006
GroPep Limited's program to develop a treatment for a condition that potentially causes 50% of all miscarriages reached a major milestone on January 9, 2006, the company said, with commencement of recruitment of healthy women volunteers into a Phase I trial of its infertility drug, PV903. The drug is targeted to treat recurrent miscarriages caused by an abnormal immune response to the fetus - a condition for which there is no current treatment. The market for a drug to treat this condition is estimated to be up to US$750 million annually. The trial, which will be conducted in Australia under the Therapeutic Goods Administration...
Source: Women's Health Law Weekly (2006-02-05)
|
